Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Divi's Labs jumps after HSBC upgrade, Street-high PT

** Divi's Laboratories DIVI.NS shares climb 2% to 7,030 rupees

** Top gainer on pharma index .NIPHARM, which is trading 0.4% lower

** HSBC Global Research upgrades stock to "buy" from "reduce"

** HSBC lifts PT to 7,900 rupee from 5,020 rupees, highest on the Street among 24 analysts, per data complied by LSEG

** Notes "long runway of growth" for DIVI led by strong demand for weight-loss drug tirzeptide, the active ingredient in Eli Lilly's LLY.N Mounjaro

** Expects revenue potential of $450 mln for DIVI from peptides such as GLP-1s by 2030

** Avg rating on DIVI is "hold"; median PT 6,460 rupees - data compiled by LSEG

** DIVI best YTD performer on 20-member pharma index with 15% climb

 (Reporting by Kashish Tandon in Bengaluru)

 ((Kashish.tandon@thomsonreuters.com))

Recent news on Divi's Laboratories

See all news